Varma Mutual Pension Insurance Co Sells 5,900 Shares of Elevance Health, Inc. $ELV

Key Points

• Varma Mutual Pension trimmed its stake in Elevance by 12.9%, selling 5,900 shares and leaving 39,882 shares valued at about $13.98 million at the end of the quarter.
• Q4 results beat expectations—EPS $12.58 vs. $10.74 and revenue $49.49B vs. $48.21B—and analysts hold a consensus "Moderate Buy" with a $384.58 price target.
• Several large investors materially increased positions (e.g., Artisan +24.5%, First Eagle +25.0%, Baupost +114.1%), leaving institutional ownership at roughly 89.24% of the stock.

Varma Mutual Pension Insurance Co trimmed its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 12.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,882 shares of the company's stock after selling 5,900 shares during the quarter. Varma Mutual Pension Insurance Co's holdings in Elevance Health were worth $13,981,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Artisan Partners Limited Partnership grew its position in Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company's stock worth $1,478,857,000 after acquiring an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC grew its position in Elevance Health by 25.0% in the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company's stock worth $1,292,029,000 after acquiring an additional 798,457 shares in the last quarter. Brave Warrior Advisors LLC grew its position in Elevance Health by 65.3% in the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company's stock worth $592,603,000 after acquiring an additional 724,349 shares in the last quarter. Baupost Group LLC MA grew its position in Elevance Health by 114.1% in the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company's stock worth $426,195,000 after acquiring an additional 703,000 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its position in Elevance Health by 44.2% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company's stock worth $660,935,000 after acquiring an additional 627,038 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft lifted their price target on Elevance Health from $332.00 to $363.00 and gave the stock a "hold" rating in a research report on Thursday, April 23rd. UBS Group set a $400.00 target price on Elevance Health in a research report on Thursday, January 29th. Citigroup upgraded Elevance Health to a "buy" rating in a research report on Wednesday, April 29th. Jefferies Financial Group dropped their target price on Elevance Health from $395.00 to $391.00 and set a "buy" rating for the company in a research report on Monday, April 20th. Finally, Robert W. Baird boosted their target price on Elevance Health from $317.00 to $331.00 and gave the company a "neutral" rating in a research report on Thursday, April 23rd. Thirteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $384.58.

Elevance Health Stock Performance

Elevance Health stock opened at $371.61 on Tuesday. The company has a 50 day moving average price of $310.69 and a 200-day moving average price of $331.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $424.24. The company has a market capitalization of $80.70 billion, a PE ratio of 15.81, a P/E/G ratio of 2.12 and a beta of 0.66.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts' consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health's revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts forecast that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.9%. Elevance Health's dividend payout ratio is presently 29.26%.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.